JP7821188B2 - カンプトテシン化合物、その調製方法、及びその適用 - Google Patents

カンプトテシン化合物、その調製方法、及びその適用

Info

Publication number
JP7821188B2
JP7821188B2 JP2023544762A JP2023544762A JP7821188B2 JP 7821188 B2 JP7821188 B2 JP 7821188B2 JP 2023544762 A JP2023544762 A JP 2023544762A JP 2023544762 A JP2023544762 A JP 2023544762A JP 7821188 B2 JP7821188 B2 JP 7821188B2
Authority
JP
Japan
Prior art keywords
compound
formula
group
reaction
carried out
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023544762A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506819A (ja
Inventor
チアン ティエン，
イータオ ジャン，
ユー ミャオ，
ボー ワン，
ジアン イェ，
シャオベイ ワン，
デリャン リー，
フェン リー，
ホンメイ ソン，
Original Assignee
シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド filed Critical シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド
Publication of JP2024506819A publication Critical patent/JP2024506819A/ja
Priority to JP2025123921A priority Critical patent/JP2025160317A/ja
Priority to JP2025123923A priority patent/JP2025160318A/ja
Application granted granted Critical
Publication of JP7821188B2 publication Critical patent/JP7821188B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023544762A 2021-02-05 2022-01-27 カンプトテシン化合物、その調製方法、及びその適用 Active JP7821188B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2025123921A JP2025160317A (ja) 2021-02-05 2025-07-24 カンプトテシン化合物、その調製方法、及びその適用
JP2025123923A JP2025160318A (ja) 2021-02-05 2025-07-24 カンプトテシン化合物、その調製方法、及びその適用

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
CN202110159956.6 2021-02-05
CN202110159956 2021-02-05
CN202110533304.4 2021-05-17
CN202110533304 2021-05-17
CN202110718245 2021-06-28
CN202110718245.8 2021-06-28
CN202110936768.X 2021-08-16
CN202110936768 2021-08-16
CN202111355330.9 2021-11-16
CN202111355330 2021-11-16
PCT/CN2022/074328 WO2022166762A1 (zh) 2021-02-05 2022-01-27 喜树碱类化合物及其制备方法和应用

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2025123921A Division JP2025160317A (ja) 2021-02-05 2025-07-24 カンプトテシン化合物、その調製方法、及びその適用
JP2025123923A Division JP2025160318A (ja) 2021-02-05 2025-07-24 カンプトテシン化合物、その調製方法、及びその適用

Publications (2)

Publication Number Publication Date
JP2024506819A JP2024506819A (ja) 2024-02-15
JP7821188B2 true JP7821188B2 (ja) 2026-02-26

Family

ID=82741966

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2023544762A Active JP7821188B2 (ja) 2021-02-05 2022-01-27 カンプトテシン化合物、その調製方法、及びその適用
JP2025123923A Pending JP2025160318A (ja) 2021-02-05 2025-07-24 カンプトテシン化合物、その調製方法、及びその適用
JP2025123921A Pending JP2025160317A (ja) 2021-02-05 2025-07-24 カンプトテシン化合物、その調製方法、及びその適用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2025123923A Pending JP2025160318A (ja) 2021-02-05 2025-07-24 カンプトテシン化合物、その調製方法、及びその適用
JP2025123921A Pending JP2025160317A (ja) 2021-02-05 2025-07-24 カンプトテシン化合物、その調製方法、及びその適用

Country Status (9)

Country Link
US (2) US20240158410A1 (enExample)
EP (3) EP4628165A3 (enExample)
JP (3) JP7821188B2 (enExample)
KR (3) KR20230142710A (enExample)
CN (3) CN116829561A (enExample)
AU (1) AU2022216696A1 (enExample)
CA (1) CA3209426A1 (enExample)
MX (1) MX2023008716A (enExample)
WO (1) WO2022166762A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301793A (en) 2020-09-30 2023-05-01 Duality Biologics Suzhou Co Ltd Anticancer compound and method for its preparation and use
EP4227310A4 (en) * 2020-10-12 2024-11-06 Sichuan Baili Pharmaceutical Co. Ltd. CAMPTOTHECIN DERIVATIVE AND LIGAND-DRUG CONJUGATE THEREOF
KR20230142710A (ko) * 2021-02-05 2023-10-11 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 캄프토테신 화합물, 그의 제조방법 및 그의 응용
AU2022315277A1 (en) 2021-07-19 2024-01-18 Immunome, Inc. Immunoconjugates and methods
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
WO2023020605A1 (zh) * 2021-08-19 2023-02-23 江苏先声药业有限公司 喜树碱衍生物、其药物组合物及其应用
US20250059143A1 (en) * 2021-10-26 2025-02-20 Shanghai Best-Link Bioscience, Llc Camptothecin derivative intermediate, and preparation method therefor and use thereof
KR20240101682A9 (ko) 2021-11-15 2025-12-10 시스트이뮨, 인코포레이티드 이중특이 항체-캄프토테신 약물 접합체 및 이의 약학적 용도
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
CN118696048A (zh) * 2022-05-09 2024-09-24 同宜医药（苏州）有限公司 一种喜树碱衍生物，基于其的抗体-药物偶联物和药物组合物，及其应用
WO2023216956A1 (zh) 2022-05-13 2023-11-16 四川科伦博泰生物医药股份有限公司 喜树碱类化合物及其制备方法和应用
IL318296A (en) 2022-07-15 2025-03-01 Genequantum Healthcare Suzhou Co Ltd Anti-TROP2 antibody and its conjugate
JP2025524985A (ja) * 2022-07-26 2025-08-01 イムノーム，インク． イムノコンジュゲート及び方法
GEAP202516720A (en) * 2022-09-02 2025-07-10 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
CN121064210A (zh) * 2022-09-09 2025-12-05 杭州爱科瑞思生物医药有限公司 喜树碱-7-乙基胺衍生物及其制备方法和应用
CN119948031A (zh) * 2022-09-30 2025-05-06 广州百济神州生物制药有限公司 依沙替康类似物的配体-药物缀合物以及其医疗用途
AU2023359114A1 (en) 2022-10-09 2025-04-24 LaNova Medicines Limited Compounds, compositions and methods
IL320396A (en) * 2022-10-25 2025-06-01 Merck Sharp & Dohme Llc Charge-linkers of anti-drug conjugates derived from extacan, pharmaceutical compositions, and uses thereof
KR20250112249A (ko) * 2022-11-22 2025-07-23 키메드 바이오사이언시스 (청두) 컴퍼니 리미티드 융합된 고리 화합물, 이의 접합체 및 이의 용도
WO2024114318A1 (zh) * 2022-11-29 2024-06-06 四川科伦博泰生物医药股份有限公司 药物连接子化合物及其制备方法和用途
CN116870187A (zh) * 2022-12-29 2023-10-13 杭州爱科瑞思生物医药有限公司 N-氧杂环烷基取代的喜树碱衍生物的抗体偶联药物
CN116712563A (zh) * 2022-12-29 2023-09-08 杭州爱科瑞思生物医药有限公司 N-卤代烷基取代的喜树碱衍生物的抗体偶联药物
CN116712562A (zh) * 2022-12-29 2023-09-08 杭州爱科瑞思生物医药有限公司 N-叠氮烷基取代的喜树碱衍生物的抗体偶联药物
WO2024158996A2 (en) * 2023-01-25 2024-08-02 Zeno Management, Inc. Immunoconjugates and methods
WO2024175069A1 (zh) * 2023-02-23 2024-08-29 一线医药（杭州）有限公司 喜树碱衍生物及其偶联物以及其制备方法和医药用途
TW202502774A (zh) * 2023-03-01 2025-01-16 大陸商江蘇恆瑞醫藥股份有限公司 一種茚并［１，２－ｂ］喹啉－１０，１３－二酮衍生物的製備方法
AU2024243250A1 (en) * 2023-04-07 2025-10-16 Changchun Genescience Pharmaceutical Co., Ltd. Camptothecin derivative, and pharmaceutical composition, preparation method therefor and use thereof
CN116478051B (zh) * 2023-04-13 2024-06-21 戊言医药科技（上海）有限公司 一种贝洛替康盐酸盐及其关键中间体的制备方法
WO2024227432A1 (zh) * 2023-04-30 2024-11-07 泰诚思(上海)生物医药有限公司 喜树碱衍生物、其制备方法及用途、抗体药物偶联物及其应用
WO2024227439A1 (zh) * 2023-05-04 2024-11-07 四川科伦博泰生物医药股份有限公司 具有靶向作用的偶联物及其制备方法和用途
CN117417346B (zh) * 2023-09-11 2025-07-25 常州合全药业有限公司 喜树碱类衍生物的制备方法
KR20250059577A (ko) 2023-10-24 2025-05-07 삼성디스플레이 주식회사 표시 장치
CN120000805A (zh) * 2023-11-15 2025-05-16 四川科伦博泰生物医药股份有限公司 靶向EGFR/c-MET的抗体-药物缀合物及其制备方法和用途
CN120058720A (zh) * 2024-01-08 2025-05-30 杭州爱科瑞思生物医药有限公司 7-含羟胺结构取代的烷基喜树碱衍生物的制备及其应用
CN120058721A (zh) * 2024-01-08 2025-05-30 杭州爱科瑞思生物医药有限公司 7-氟烷基取代的喜树碱衍生物的制备及其应用
WO2025162049A1 (zh) * 2024-02-02 2025-08-07 长春金赛药业有限责任公司 卤代烯烃类喜树碱衍生物、药物组合物及其制备方法和应用
WO2025242090A1 (zh) * 2024-05-21 2025-11-27 康诺亚生物医药科技（成都）有限公司 喜树碱衍生物及其中间体的制备方法
WO2026046398A1 (en) * 2024-08-30 2026-03-05 Hansoh Bio Llc Novel camptothecin derivative and conjugate thereof, preparation method therefor and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195665A1 (en) 2018-04-06 2019-10-10 Seattle Genetics, Inc. Camptothecin peptide conjugates
WO2019236954A1 (en) 2018-06-07 2019-12-12 Seattle Genetics, Inc. Camptothecin conjugates
WO2020219287A1 (en) 2019-04-26 2020-10-29 Immunogen, Inc. Camptothecin derivatives

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3008226B2 (ja) * 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
ES2184882T3 (es) * 1995-06-21 2003-04-16 Sod Conseils Rech Applic Nuevos analogos de la camptotecina, procedimiento de preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
CA2192725C (en) * 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
CN100408582C (zh) * 2004-02-12 2008-08-06 中国人民解放军第二军医大学 高喜树碱类化合物及其制备方法和用途
WO2017176648A1 (en) * 2016-04-04 2017-10-12 Rutgers, The State University Of New Jersey Topoisomerase poisons
WO2019011170A1 (zh) * 2017-07-14 2019-01-17 四川科伦博泰生物医药股份有限公司 噁二唑类衍生物、其制备方法及其在医药上的应用
EP4667495A3 (en) * 2017-12-15 2026-03-11 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Bioactive molecule conjugate, preparation method and use thereof
AU2019349207B2 (en) * 2018-09-26 2026-01-08 Jiangsu Hengrui Medicine Co., Ltd. Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof
JP7408646B2 (ja) * 2018-09-30 2024-01-05 ジエンス ハンソー ファーマスーティカル グループ カンパニー リミテッド 抗－ｂ７ｈ３抗体－エキサテカンアナログコンジュゲート及びその医薬用途
CN118221763A (zh) * 2019-03-29 2024-06-21 免疫医疗有限公司 化合物及其缀合物
CN111689980A (zh) * 2019-05-26 2020-09-22 四川百利药业有限责任公司 一种喜树碱药物及其抗体偶联物
CN110357897A (zh) * 2019-07-26 2019-10-22 上海健康医学院 一种具有抗肿瘤活性的喜树碱衍生物及其制备方法和应用
JP7467610B2 (ja) * 2019-09-18 2024-04-15 バイリ－バイオ（チェンドゥ）ファーマスーティカル シーオー．，エルティーディー． カンプトテシン誘導体及びその複合体
US20230101735A1 (en) * 2020-01-22 2023-03-30 Jiangsu Hengrui Medicine Co., Ltd. Anti-trop-2 antidody-exatecan analog conjugate and medical use thereof
KR20230022211A (ko) * 2020-06-08 2023-02-14 바이리-바이오 (청두) 파마슈티칼 컴퍼니, 리미티드 고안정성 친수성 연결 단위를 갖는 캄프토테신 약물 및 이의 접합체
CN113943310A (zh) * 2020-10-12 2022-01-18 四川百利药业有限责任公司 一种氘代的喜树碱衍生物及其抗体药物偶联物
KR20230142710A (ko) * 2021-02-05 2023-10-11 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 캄프토테신 화합물, 그의 제조방법 및 그의 응용
KR20240016249A (ko) * 2021-06-02 2024-02-06 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항체 약물 접합체, 이의 제조 방법, 및 이의 용도
WO2022253033A1 (zh) * 2021-06-02 2022-12-08 四川科伦博泰生物医药股份有限公司 一类化学偶联连接子及其用途
US11814394B2 (en) * 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
CN117567487A (zh) * 2023-11-27 2024-02-20 金宏气体股份有限公司 双核Ag(I)配合物晶体、制备方法、负载物、装置及应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195665A1 (en) 2018-04-06 2019-10-10 Seattle Genetics, Inc. Camptothecin peptide conjugates
WO2019236954A1 (en) 2018-06-07 2019-12-12 Seattle Genetics, Inc. Camptothecin conjugates
WO2020219287A1 (en) 2019-04-26 2020-10-29 Immunogen, Inc. Camptothecin derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ACS Medicinal Chemistry Letters，2019年，10(10)，P.1386-1392

Also Published As

Publication number Publication date
KR20250120438A (ko) 2025-08-08
EP4613335A2 (en) 2025-09-10
KR20230142710A (ko) 2023-10-11
EP4628165A3 (en) 2026-03-11
US20240158410A1 (en) 2024-05-16
KR20250119655A (ko) 2025-08-07
CA3209426A1 (en) 2022-08-11
EP4613335A3 (en) 2025-12-10
CN117567478B (zh) 2025-03-21
EP4628165A2 (en) 2025-10-08
CN117567478A (zh) 2024-02-20
WO2022166762A1 (zh) 2022-08-11
MX2023008716A (es) 2023-08-02
AU2022216696A1 (en) 2023-08-17
EP4289851A4 (en) 2025-10-15
JP2025160318A (ja) 2025-10-22
CN120058723A (zh) 2025-05-30
JP2025160317A (ja) 2025-10-22
JP2024506819A (ja) 2024-02-15
CN116829561A (zh) 2023-09-29
US20250346606A1 (en) 2025-11-13
EP4289851A1 (en) 2023-12-13

Similar Documents

Publication Publication Date Title
JP7821188B2 (ja) カンプトテシン化合物、その調製方法、及びその適用
JP2025515988A (ja) カンプトテシン化合物、その調製方法及びその使用
CN101495486B (zh) 具有抗肿瘤活性的喜树碱衍生物
CN106061990B (zh) 一种阿比特龙衍生物及其制备方法和医药用途
JP2023552610A (ja) 新規カンプトテシン誘導体、それを含む組成物およびその使用
JP2025526425A (ja) 抗体薬物複合体に適した毒素分子
CN115124533A (zh) 四环类衍生物、其制备方法和其医药上的用途
CN101495485B (zh) 具有抗肿瘤活性的喜树碱衍生物
WO2025036489A1 (zh) 一种氰基芳香环衍生物及其在医药上的应用
HK40101679A (zh) 喜树碱类化合物及其制备方法和应用
HK40101679B (zh) 喜树碱类化合物及其制备方法和应用
CN120858098A (zh) 稠环化合物及其制备方法和应用
KR20260033013A (ko) 암을 치료 또는 예방하기 위한 캄프토테신 유도체 및 이의 항체-약물 접합체
CN120053678A (zh) 一种高喜树碱类抗体偶联药物、其制备方法及应用
JP5198447B2 (ja) 抗腫瘍活性を有するカンプトテシン誘導体
HK1135692B (en) Camptothecin derivatives with antitumor activity
HK1135693B (en) Camptothecin derivatives with antitumor activity
HK1135691B (en) Camptothecin derivatives with antitumor activity

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260123

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260213

R150 Certificate of patent or registration of utility model

Ref document number: 7821188

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150